Exploring Progression-Free Survival 2 (PFS2) Endpoint Trends and Uptake in the US Healthcare Landscape

Author(s)

Okorozo P1, Daniel I2, Sander J2
1Avalere Health, Buffalo, NY, USA, 2Avalere Health, New York City, NY, USA

OBJECTIVES: Overall survival (OS) is often considered to be the gold standard primary endpoint for demonstrating clinical efficacy in oncology trials and universally accepted by regulatory agencies. However, there are challenges to presenting mature OS data. There is growing interest in alternative endpoints like PFS2, which is also considered an accepted endpoint by many stakeholders for efficacy in clinical trials. This study assesses the relevance of PFS2 in the US healthcare system and acceptance by the FDA.

METHODS: FDA guidance for the oncology trials was reviewed to determine regulatory requirements for clinical endpoints. A US landscape assessment through secondary research was conducted to examine trends in the use of PFS2 within the US healthcare system including its application in clinical trials. The ClinicalTrials.gov database was searched to identify studies that include PFS2 within the last 5 years.

RESULTS: The latest FDA guidance outlining clinical trial endpoints for the approval of cancer drugs and biologics does not include PFS2 in its general endpoint considerations, despite published studies demonstrating a positive correlation between PFS2 and OS. Adhering to the FDA guidance, submissions for oncology drugs in the US had not previously integrated PFS2 until 2022, after which it has been leveraged as a secondary endpoint in evidence packages. ClinicalTrials.gov lists over 174 active or recruiting oncology trials, spanning January 2019 to January 2024, incorporating PFS2 as a primary or secondary endpoint.

CONCLUSIONS: Although the FDA has not formally recognized PFS2 in its guidance or historically relied on PFS2 findings for approval decisions, emerging evidence suggests its potential as a valuable secondary efficacy endpoint, leading to its increased adoption in clinical trials. While uncertainties persist, there exists a prospective opportunity to leverage PFS2 findings in future FDA submissions, pending FDA acceptance of PFS2 and the assurance of addressing potential biases and confounders adequately.

Conference/Value in Health Info

2024-05, ISPOR 2024, Atlanta, GA, USA

Value in Health, Volume 27, Issue 6, S1 (June 2024)

Code

CO198

Topic

Clinical Outcomes, Health Technology Assessment

Topic Subcategory

Comparative Effectiveness or Efficacy, Decision & Deliberative Processes

Disease

No Additional Disease & Conditions/Specialized Treatment Areas, Oncology

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×